CN Patent

CN110036007B — 吡啶化合物

Assigned to Daiichi Sankyo Co Ltd · Expires 2021-10-15 · 5y expired

What this patent protects

本发明涉及具有RET激酶抑制作用的化合物或其药学上可接受的盐，所述化合物或其药学上可接受的盐可用于治疗疾病，诸如癌症。特别是如本文定义的由以下通式(I)表示的化合物：或其药学上可接受的盐。

USPTO Abstract

本发明涉及具有RET激酶抑制作用的化合物或其药学上可接受的盐，所述化合物或其药学上可接受的盐可用于治疗疾病，诸如癌症。特别是如本文定义的由以下通式(I)表示的化合物：或其药学上可接受的盐。

Drugs covered by this patent

ensartinib-hydrochloride (ENSARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN110036007B
Jurisdiction: CN
Classification: —
Expires: 2021-10-15
Drug substance claim: No
Drug product claim: No
Assignee: Daiichi Sankyo Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.